Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 421 to 435 of 1003 results for public health medicine & health

  1. Norucholic acid for treating primary sclerosing cholangitis [ID6583]

    In development Reference number: GID-TA11782 Expected publication date: TBC

  2. Apraglutide for treating short bowel syndrome [ID6533]

    Awaiting development Reference number: GID-TA11695 Expected publication date: TBC

  3. Capivasertib with abiraterone for treating hormone-sensitive metastatic prostate cancer with PTEN deficiency [ID6466]

    Awaiting development Reference number: GID-TA11583 Expected publication date: TBC

  4. Trastuzumab deruxtecan for adjuvant treatment of high-risk HER2-positive residual invasive breast cancer after neoadjuvant chemotherapy [ID6509]

    Awaiting development Reference number: GID-TA11658 Expected publication date: TBC

  5. Itepekimab as add-on maintenance treatment for moderate to severe chronic obstructive pulmonary disease [ID6547]

    Awaiting development Reference number: GID-TA11716 Expected publication date: TBC

  6. Pimicotinib for treating tenosynovial giant cell tumours when systemic treatment is needed [ID6647]

    In development Reference number: GID-TA11859 Expected publication date: TBC

  7. Atezolizumab with chemotherapy for adjuvant treatment of stage 3 colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID6646]

    In development Reference number: GID-TA11858 Expected publication date: TBC

  8. Impetigo: antimicrobial prescribing (NG153)

    This guideline sets out an antimicrobial prescribing strategy for adults, young people and children aged 72 hours and over with impetigo. It aims to optimise antibiotic use and reduce antibiotic resistance.

  9. Who can register as a stakeholder?

    Find out more about the types of organisations that can register to be a stakeholder at NICE.

  10. Who can register as a stakeholder?

    Find out more about the types of organisations that can register to be a stakeholder at NICE.

  11. Learning disabilities and behaviour that challenges: service design and delivery (NG93)

    This guideline covers services for children, young people and adults with a learning disability (or autism and a learning disability) and behaviour that challenges. It aims to promote a lifelong approach to supporting people and their families and carers, focusing on prevention and early intervention and minimising inpatient admissions.

  12. Inebilizumab for treating AQP4-IgG-seropositive neuromyelitis optica spectrum disorders [ID6430]

    Awaiting development Reference number: GID-TA11530 Expected publication date: TBC

  13. Mezigdomide with dexamethasone and carfilzomib for treating relapsed or refractory multiple myeloma after at least 1 line of treatment [ID6513]

    Awaiting development Reference number: GID-TA11660 Expected publication date: TBC

  14. Icotrokinra for treating moderate to severe plaque psoriasis in people 12 years and over [ID6579]

    In development Reference number: GID-TA11780 Expected publication date: TBC

  15. Masitinib with riluzole for treating amyotrophic lateral sclerosis [ID6257]

    In development Reference number: GID-TA11071 Expected publication date: TBC